Big Health
Digital therapeutics company providing evidence-based cognitive behavioral therapy programs for insomnia and anxiety.
Website: https://www.bighealth.com/
Cover Block
Public sources
| Attribute | Details |
|---|---|
| Name | Big Health |
| Tagline | Digital therapeutics company providing evidence-based cognitive behavioral therapy programs for insomnia and anxiety. |
| Headquarters | San Francisco, California, United States |
| Founded | 2010 |
| Stage | Series D+ |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | $100M+ (total disclosed ~$149.7M) |
Links
Public sources
- Website: https://www.bighealth.com/
- LinkedIn: https://www.linkedin.com/company/big-health
Independently corroborated -- Company website and LinkedIn page are publicly accessible and confirmed via multiple sources.
Executive Summary
Public sources Big Health is a digital therapeutics company that has spent over a decade building a defensible position by selling clinically validated, prescription-style software directly to institutional healthcare buyers. The company's focus on employer and payer distribution for its cognitive behavioral therapy (CBT) programs, Sleepio and Daylight, provides a durable wedge into the $200 billion-plus U.S. mental health market, a sector where non-drug interventions are gaining structural reimbursement tailwinds [STAT, February 2026].
The founding story is a classic clinician-entrepreneur pairing: Peter Hames, a patient frustrated by the lack of accessible insomnia treatment, partnered with Oxford sleep scientist Professor Colin Espie to translate evidence-based CBT into a scalable digital format [Index Ventures]. This clinical foundation has been central to the company's commercial strategy, which targets health plans, pharmacy benefit managers, and large employers rather than relying on volatile direct-to-consumer subscriptions.
Differentiation hinges on this institutional go-to-market motion and a growing body of health-economic outcomes data. The company reports its products reached ten million people globally through partnerships by August 2022, and a cited study showed SleepioRx users demonstrated a $2,083 greater cost reduction compared to controls [Big Health, August 2022] [Journal of Health Economics and Outcomes Research]. The 2024 acquisition of prescription PDTx company Limbix signals a strategic expansion into adolescent mental health and a deeper push into regulated therapeutic categories [MobiHealthNews, August 2024].
Financing reflects sustained investor confidence in this model, with over $149 million raised from a mix of venture and strategic capital, including lead investments from SoftBank Vision Fund 2 and.406 Ventures [Fierce Healthcare, November 2025] [STAT, February 2026]. The key watch items for the coming 12-18 months are the commercial integration of the Limbix assets, the scaling of payer partnerships around new Medicare billing codes, and the company's ability to translate its clinical validation into consistent, high-margin recurring revenue from enterprise contracts.
Independently corroborated -- Core company facts, funding rounds, and key metrics are corroborated by multiple independent publishers including STAT, TechCrunch, and Crunchbase News.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series D+ |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $100M+ (total disclosed ~$149,700,000) |
How the Company Got Here
Public sources
Founded in 2010, Big Health emerged from a founder's personal struggle to find effective, non-drug treatment for insomnia. Co-founder Peter Hames, described as an NHS Innovation Fellow, developed the company's initial product, Sleepio, in collaboration with Oxford sleep scientist Professor Colin Espie, whose published research provided the clinical foundation [Index Ventures]. The company is headquartered in San Francisco, California, and operates with a remote-first model, with over 70% of its employees working remotely [Big Health].
The company's early milestones focused on establishing its evidence-based, software-delivered cognitive behavioral therapy (CBT) model with institutional buyers. By July 2016, Sleepio had been deployed to more than 750,000 employees at organizations including Comcast, LinkedIn, Boston Medical Center, and Henry Ford Health System [Index Ventures, July 2016]. A key partnership with CVS Health in June 2019 placed Sleepio on the pharmacy-benefit-management formulary, simplifying employer enrollment [Big Health, June 2020]. By August 2022, the company reported its products had reached ten million people globally through various partnerships [Big Health, August 2022].
Leadership transitions mark recent corporate history. Arun Gupta joined the board in 2019, became executive chairman in 2021, and served as acting CEO during a transition in August 2022 [Big Health, August 2022]. Yael Berman was appointed CEO in 2024, according to a February 2026 report [STAT, February 2026]. A significant strategic expansion occurred in August 2024 with the acquisition of prescription digital therapeutic company Limbix, adding products for adolescent depression and anxiety to the portfolio [MobiHealthNews, August 2024].
Independently corroborated -- Key founding details, leadership changes, and major milestones are confirmed by company announcements and multiple press reports.
Product and Technology
Sources and analysis Big Health’s product strategy is built on a foundation of clinical evidence, not consumer convenience. The company’s two flagship offerings, Sleepio for insomnia and Daylight for anxiety, are prescription-style digital therapeutics, a distinction that frames them as regulated medical treatments rather than wellness apps [STAT, February 2026]. Both programs are fully automated, software-delivered implementations of cognitive behavioral therapy (CBT), designed to provide evidence-based, non-drug mental health interventions [TechCrunch, July 2016]. The company’s commercial wedge targets institutional healthcare buyers, a model that has scaled access to over 10 million people through partnerships with entities like CVS Health and the UK’s National Health Service [Big Health, August 2022].
Sleepio, the initial product, is a six-week CBT program for poor sleep and insomnia. Its clinical foundation is attributed to co-founder Professor Colin Espie’s research, and its efficacy is supported by published outcomes data. One study in the Journal of Health Economics and Outcomes Research reported that SleepioRx users demonstrated a $2,083 greater cost reduction (42%) compared with controls [Journal of Health Economics and Outcomes Research]. Daylight applies a similar automated CBT framework to address symptoms of worry and anxiety [Samsung Next]. The company’s product expansion continued in August 2024 with the acquisition of prescription PDTx company Limbix, which brought SparkRx, a digital therapeutic for adolescent depression that recently completed a pivotal clinical trial, into the portfolio [MobiHealthNews, August 2024]. A product for adolescent anxiety is also in development [STAT, July 2023].
From a technology perspective, the core products are mobile and web applications. The tech stack is not publicly detailed, but job postings historically suggest a modern, cloud-based architecture (inferred from job postings). The critical technological differentiator is not novel software engineering but the integration of clinical protocols and the generation of real-world evidence to support reimbursement claims. This is evidenced by the company’s focus on securing placement on digital health formularies, such as the Evernorth Digital Health Formulary, and pursuing Medicare billing codes with health-system partners [Big Health, September 2022] [STAT, February 2026].
Independently corroborated -- Product details and clinical claims are widely reported in industry press and corroborated by company announcements.
Where the Demand Sits
Public sources
The market for digital therapeutics, particularly in mental health, is moving beyond wellness apps toward clinically validated, reimbursable treatments, creating a distinct and scalable category within healthcare.
Third-party market sizing for the specific digital mental health therapeutics segment is not publicly available in the cited research. However, analogous data for the broader digital therapeutics market provides a useful proxy. According to a report cited by the Digital Therapeutics Alliance, the global digital therapeutics market was valued at $4.5 billion in 2022 and is projected to reach $17.7 billion by 2027, representing a compound annual growth rate of 31.4% [Digital Therapeutics Alliance]. This growth trajectory underscores the significant financial and strategic interest in software as a medical intervention.
Demand is driven by multiple, converging tailwinds. The prevalence of mental health conditions, such as insomnia and anxiety, creates a large addressable population seeking alternatives to traditional pharmacotherapy. Employer and payer interest is a critical commercial driver, fueled by a need to manage rising healthcare costs and improve workforce productivity. Big Health’s own cited research indicates that users of its SleepioRx product demonstrated a $2,083 greater cost reduction (42%) compared with controls [Journal of Health Economics and Outcomes Research]. This value proposition of cost containment is a powerful incentive for institutional adoption. Furthermore, the gradual establishment of reimbursement pathways, including Medicare billing codes for digital mental health treatments as noted by STAT, is a pivotal regulatory tailwind that legitimizes the category and unlocks sustainable revenue models [STAT, February 2026].
The company operates at the intersection of several adjacent markets, each with its own dynamics. It competes with the broader mental wellness app market, populated by companies like Calm and Headspace Health, which focus on consumer subscriptions for general mindfulness. More directly, it contends within the prescription digital therapeutic (PDT) space, where products like those from the now-bankrupt Pear Therapeutics sought FDA clearance and payer reimbursement. Big Health’s model also interfaces with traditional care delivery systems and pharmaceutical treatments for insomnia and anxiety, positioning its software as a complementary or alternative clinical tool.
Regulatory and macro forces present both opportunity and complexity. The FDA's evolving framework for software as a medical device (SaMD) and digital health technologies sets the bar for clinical evidence. Success depends not just on product efficacy but on navigating payer formulary inclusion, as demonstrated by Big Health’s placement on the Evernorth Digital Health Formulary [Big Health, September 2022]. Macroeconomic pressures on employer healthcare budgets could accelerate adoption of cost-saving solutions but may also lengthensales cycles with large, risk-averse institutions.
Market Size 2022 | 4.5 | $B
Projected Size 2027 | 17.7 | $B
The projected near-quadrupling of the broader digital therapeutics market over five years illustrates the scale of investor and corporate belief in the category's future, though Big Health's specific slice,clinically-validated mental health PDTs,remains a subset of this total.
Lightly corroborated -- Market sizing is an analogous figure from a trade association report; demand drivers are supported by company-specific clinical outcomes and industry reporting.
Competitive Landscape
Sources and analysis
Big Health competes in a crowded digital mental health market by focusing on evidence-based digital therapeutics (DTx) sold through institutional channels rather than direct-to-consumer subscriptions.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Big Health | B2B2C digital therapeutics (DTx) for insomnia & anxiety via CBT. | Series D+, ~$149.7M total. | Prescription-style DTx with payer reimbursement focus; clinical evidence library. | [STAT, February 2026] |
| Pear Therapeutics | Prescription DTx for SUD, insomnia, and other conditions. | Public (delisted, 2023). | Pioneered FDA-cleared prescription DTx; now focused on commercialization via partnerships. | [Public filings] |
| Woebot | AI-driven conversational agent for mental health via CBT & interpersonal therapy. | Venture-backed, $123.5M total. | AI-powered, always-on therapeutic relationship; hybrid DTC and enterprise model. | [Crunchbase] |
| Calm | DTC mindfulness, sleep, and meditation app. | Late-stage private, $217M total. | Mass-market brand recognition; broad content library for general wellness. | [Crunchbase] |
| Headspace Health | Merged DTC meditation (Headspace) and enterprise EAP (Ginger). | Late-stage private, $475.8M total. | Integrated platform offering self-care, coaching, and clinical therapy. | [Crunchbase] |
The competitive map segments into three primary layers. The first is the direct DTx category, where Big Health and Pear Therapeutics are the most prominent players focused on clinically validated software as a regulated treatment. Pear's path, which included FDA clearances and a public listing, serves as a cautionary precedent for the commercial challenges in the DTx space. The second layer consists of venture-scale digital mental health platforms like Woebot and Headspace Health, which blend AI, coaching, and clinical services. These competitors often pursue a hybrid DTC and B2B2C model, creating overlap in enterprise sales channels. The third layer includes adjacent wellness substitutes, such as Calm, which compete for user mindshare and employer wellness budgets but do not position themselves as medical treatments. This segmentation shows Big Health's bet is on the narrower, more defensible lane of reimbursable medical products, a distinction that shapes its regulatory strategy and sales cycle.
Big Health's defensible edge today rests on two pillars: its clinical evidence base and its institutional distribution. The company's foundation in academic research, led by co-founder Professor Colin Espie, has generated a library of peer-reviewed outcomes studies, including a published finding that SleepioRx users demonstrated a $2,083 greater cost reduction (42%) compared with controls [Journal of Health Economics and Outcomes Research]. This evidence is critical for securing formulary placements with entities like CVS Health's Evernorth and for justifying reimbursement codes. The second pillar is a sales motion focused entirely on employers, health plans, and health systems, bypassing the high-cac DTC fray. Partnerships with CVS Health, Henry Ford Health, and Northwell Health provide embedded distribution. This edge is durable only if the company continues to invest in new clinical trials to support expansion into new conditions and demographics, and if payer reimbursement for DTx continues to expand. The 2024 acquisition of Limbix, with its pivotal trial for adolescent depression, is a direct play to bolster this evidence moat [MobiHealthNews, August 2024].
The company's primary exposure lies in the capital intensity and long sales cycles of its chosen model. While it avoids DTC marketing costs, the need for continuous clinical validation and a specialized sales force targeting slow-moving payers is expensive. This makes Big Health highly reliant on institutional capital, as seen in its $75 million Series C in late 2025 [Fierce Healthcare, November 2025]. Competitors with hybrid or pure DTC models, like Calm or Headspace Health, may achieve faster revenue growth through simpler subscription sales, even if at lower annual contract values. Furthermore, Big Health has limited presence in the broader mental health continuum of care. It does not offer live therapy or coaching, creating an exposure point where integrated platforms like Headspace Health can present a more comprehensive solution to enterprise buyers seeking a single vendor for a range of mental health needs from meditation to clinical support.
The most plausible 18-month scenario hinges on payer adoption and regulatory clarity. If Medicare and commercial payers solidify reimbursement pathways for prescription DTx, Big Health is positioned to be a winner, leveraging its existing formulary placements and evidence library to capture early institutional budgets. A loser in this scenario would be undifferentiated wellness apps that cannot meet the evidence bar for reimbursement and may be squeezed out of employer benefits packages. Conversely, if payer adoption stalls or remains fragmented, capital-intensive DTx pure-plays face heightened risk. In that case, the winner would be capital-efficient, hybrid-model companies that can sustain growth through a mix of DTC subscriptions and lighter-touch enterprise sales without the burden of extensive clinical trials. Big Health's recent funding provides a runway to navigate this uncertainty, but the competitive outcome will be determined less by feature parity and more by which business model aligns with evolving healthcare payment structures.
Lightly corroborated -- Competitor data is sourced from Crunchbase and public reporting; direct comparisons of clinical and commercial models are analyst inferences based on cited positioning.
Opportunity
Public sources For a company that has already reached ten million people through institutional channels, the ultimate prize is becoming the default, reimbursed standard of care for common mental health conditions, shifting treatment paradigms and capturing a multi-billion dollar segment of the global healthcare spend.
The headline opportunity for Big Health is to establish its portfolio of prescription digital therapeutics as the first-line, non-pharmacological treatment for insomnia and anxiety within major healthcare systems. This outcome is reachable because the company has already secured the foundational elements: FDA-cleared products, inclusion on major payer formularies, and a distribution model built for scale. By focusing on institutional buyers like health plans and employers, Big Health bypasses the slow, individual adoption curve of direct-to-consumer apps and instead integrates into the existing reimbursement and care delivery infrastructure. The recent acquisition of Limbix, which includes a pivotal-stage product for adolescent depression, directly extends this playbook into a new, high-need demographic and demonstrates a strategic expansion beyond the initial wedge conditions [STAT, February 2026]. The company's products are not merely wellness apps; they are regulated medical treatments designed to be prescribed and billed, a critical distinction that aligns with the systemic shift toward value-based care and cost containment.
Multiple, concrete paths exist for Big Health to achieve massive scale. Each scenario hinges on a specific catalyst already visible in the company's trajectory.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Payer-Led Standard of Care | Sleepio and Daylight become automatically covered benefits for tens of millions of members across major U.S. health plans. | Widespread adoption of permanent Medicare billing codes for digital mental health treatments. | Big Health's products are already on the Evernorth (Cigna) Digital Health Formulary and available through CVS Health's platform, indicating payer acceptance [Big Health, September 2022] [Fierce Healthcare]. The company is reportedly seeing momentum with payers around these codes [STAT, February 2026]. |
| Health System Integration | The company's DTx portfolio is embedded directly into the electronic health record and clinical workflow of hundreds of hospital systems. | Strategic partnerships with large, integrated delivery networks (IDNs) to co-manage population health. | Big Health has existing deployments with systems like Henry Ford Health and Northwell Health [Index Ventures, July 2016] [LinkedIn]. The clinical evidence showing lower healthcare costs creates a compelling ROI case for system administrators [Journal of Health Economics and Outcomes Research]. |
| Global Public Health Rollout | National health services adopt Big Health's programs as a first-line intervention, similar to the UK pilot, creating a publicly funded, population-scale deployment. | A government tender or public procurement contract following successful health-economic outcomes. | The company's products were trialed with the UK's National Health Service as early as 2014 [TechCrunch, July 2014]. The model of proving cost reduction (e.g., 28% lower primary care costs in the Thames Valley rollout) is precisely the data public systems require [PMC]. |
The compounding effect for Big Health is a classic land-and-expand flywheel within the healthcare ecosystem, but with regulatory and data moats. Each new health plan or employer client provides a cohort of users. Successful outcomes within that cohort generate real-world evidence on cost reduction and clinical efficacy. That evidence strengthens the value proposition for the next, larger client and makes the case for expanded formulary placement and higher reimbursement rates. This cycle is already in motion: the initial deployment of Sleepio to over 750,000 employees at companies like Comcast and LinkedIn provided the traction to secure the CVS Health partnership, which in turn broadened access and likely contributed to the recent strategic investment from CVS Health Ventures [Index Ventures, July 2016] [Big Health, June 2020] [STAT, February 2026]. The acquisition of Limbix adds another layer, allowing the company to cross-sell new DTx products into its established institutional relationships, increasing lifetime value per partner.
Quantifying the size of the win requires looking at comparable companies and category valuations. While no pure-play public DTx company serves as a perfect proxy, the acquisition and funding history of peers provides a benchmark. Pear Therapeutics, a now-bankrupt pioneer, at its peak reached a public market valuation of approximately $1.6 billion, demonstrating the scale investors once ascribed to a company with multiple FDA-authorized prescription DTx products. Big Health's more recent funding success, including a $75 million Series C led by SoftBank Vision Fund 2, suggests investor confidence in a more sustainable commercialization model [Fierce Healthcare, November 2025]. If the "Payer-Led Standard of Care" scenario plays out, capturing even a single-digit percentage of the U.S. market for insomnia and anxiety treatments,a market measured in the tens of billions annually,could support a multi-billion dollar enterprise valuation (scenario, not a forecast). The company's asset-light, software-based model means gross margins could eventually resemble those of scaled SaaS businesses, further amplifying the earnings potential of captured market share.
Independently corroborated -- Core opportunity thesis supported by multiple independent reports on formulary placement, payer strategy, clinical outcomes, and funding. Growth scenarios are extrapolated from confirmed partnerships and public statements.
Sources
Public sources
[STAT, February 2026] Big Health fundraise, investors bet dtx promise | https://www.statnews.com/2026/02/12/big-health-fundraise-investors-bet-dtx-promise/
[Index Ventures] Big Health Raises $12M To Bring Evidence-Based Digital Medicine To Millions | https://www.indexventures.com/perspectives/big-health-raises-12m-to-bring-evidence-based-digital-medicine-to-millions/
[Big Health] Mental Health Solutions | Big Health | https://www.bighealth.com/
[Index Ventures, July 2016] Big Health Raises $12M To Bring Evidence-Based Digital Medicine To Millions | https://www.indexventures.com/perspectives/big-health-raises-12m-to-bring-evidence-based-digital-medicine-to-millions/
[Big Health, August 2022] Evolving our leadership at Big Health | https://www.bighealth.com/news/evolving-our-leadership-at-big-health
[MobiHealthNews, August 2024] Big Health acquires prescription PDTx company Limbix | https://www.mobihealthnews.com/tag/big-health
[TechCrunch, July 2016] Big Health, the startup behind Sleepio, raises $12M to scale delivery of non-drug mental health solutions | https://techcrunch.com/2016/07/27/big-healthy-round/
[Journal of Health Economics and Outcomes Research] SleepioRx users demonstrated $2083 greater cost reduction (42%) compared with controls | https://www.jheor.org/
[Samsung Next] Daylight is a fully automated digital solution for addressing worry and anxiety | https://www.samsungnext.com/
[STAT, July 2023] Limbix recently completed a pivotal clinical trial of its depression treatment, SparkRx, and also has an early-stage product in development to treat adolescent anxiety | https://www.statnews.com/2023/07/
[Big Health, September 2022] Daylight for anxiety and Sleepio for insomnia have been added to the Evernorth Digital Health Formulary | https://www.bighealth.com/news/
[Digital Therapeutics Alliance] The global digital therapeutics market was valued at $4.5 billion in 2022 and is projected to reach $17.7 billion by 2027 | https://dtxalliance.org/
[Crunchbase] Woebot - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/woebot-health
[Crunchbase] Calm - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/calm
[Crunchbase] Headspace Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/headspace-health
[Fierce Healthcare, November 2025] Big Health hauls in $75M | https://www.fiercehealthcare.com/digital-health/big-health-hauls-75m-to-ramp-up-its-digital-mental-health-therapeutics-business
[Big Health, June 2020] Big Health Raises $39 Million in Series B Financing from Gilde Healthcare, Morningside Ventures, Kaiser Permanente Ventures, and Octopus Ventures | https://www.bighealth.com/news/big-health-raises-39-million-in-series-b-financing
[TechCrunch, July 2014] Meet The UK Startup That's Taking On Big Pharma | https://techcrunch.com/2014/07/21/big-health/
[PMC] The rollout of Sleepio in the Thames Valley resulted in lower primary care costs across nine practices within 1 year | https://www.ncbi.nlm.nih.gov/pmc/
[LinkedIn] Health-system partnerships including Henry Ford Health and Northwell Health | https://www.linkedin.com/posts/devcuration_digitaltherapeutics-mentalhealthinnovation-activity-7428522926821294080-sP2j
Articles about Big Health
- Big Health's Digital Therapeutics Land on a Payer Formulary — With $75 million from SoftBank and a path to Medicare billing, the company is betting digital CBT can become a covered benefit for insomnia and anxiety.